| Date | Name | Title | Type | Security | Shares | Price | Value | Ownership | Reported |
| 06/14/2023 | Hitchcock Michael J.M. | Director | Grant | Stock Option (Right to Buy) | 7k | $38.90 | $271.9k | | 06/14/2023 |
| 06/14/2023 | Faust Elizabeth | Director | Grant | Stock Option (Right to Buy) | 7k | $38.90 | $271.9k | | 06/14/2023 |
| 06/14/2023 | Chen Bihua | 10% Owner | Grant | Stock Option (right to buy) | 7k | $38.90 | $271.9k | | 06/14/2023 |
| 06/14/2023 | AGUIAR ERIC | Director | Grant | Stock Option (Right to Buy) | 7k | $38.90 | $271.9k | | 06/14/2023 |
| 06/14/2023 | Ray Sumita | Director | Grant | Stock Option (Right to Buy) | 7k | $38.90 | $271.9k | | 06/14/2023 |
| 06/01/2023 | A2A Pharmaceuticals, Inc. | 10% Owner | Sale | Common Stock | 50k | $34.56 | $1.7M | | 05/31/2023 |
| 05/31/2023 | A2A Pharmaceuticals, Inc. | 10% Owner | Sale | Common Stock | 75k | $33.81 | $2.5M | | 05/31/2023 |
| 05/31/2023 | Valle Franco | CFO | Grant | Common Stock | 4.3k | $3.78 | $16.2k | | 05/31/2023 |
| 05/12/2023 | A2A Pharmaceuticals, Inc. | 10% Owner | Sale | Common Stock | 25k | $33.84 | $846k | | 05/12/2023 |
| 05/09/2023 | A2A Pharmaceuticals, Inc. | 10% Owner | Sale | Common Stock | 150k | $34.50 | $5.2M | | 05/08/2023 |
| 05/08/2023 | A2A Pharmaceuticals, Inc. | 10% Owner | Sale | Common Stock | 100k | $33.99 | $3.4M | | 05/08/2023 |
| 03/30/2023 | Chen Bihua | 10% Owner | Purchase | Common Stock | 400k | $30.00 | $12M | See Footnotes | 03/30/2023 |
| 01/06/2023 | Valle Franco | CFO | Grant | Stock Option (Right to Buy) | 126.3k | $7.05 | $890.4k | | 01/06/2023 |
| 01/06/2023 | Erdtmann Rainer M | President and COO | Grant | Stock Option (Right to Buy) | 118k | $7.05 | $831.9k | | 01/06/2023 |
| 01/06/2023 | Butler Thomas Andrew | CEO | Grant | Stock Option (Right to Buy) | 354.4k | $7.05 | $2.5M | | 01/06/2023 |
| 11/30/2022 | Valle Franco | CFO | Grant | Common Stock | 2.5k | $3.78 | $9.5k | | 11/30/2022 |
| 11/14/2022 | Hitchcock Michael J.M. | Director | Purchase | Common Stock | 5k | $7.93 | $39.6k | | 11/14/2022 |
| 08/16/2022 | A2A Pharmaceuticals, Inc. | 10% Owner | Purchase | Common Stock | 30.7k | $13.87 | $425.6k | | 08/16/2022 |
| 07/21/2022 | A2A Pharmaceuticals, Inc. | 10% Owner | Sale | Common Stock | 34.7k | $11.21 | $388.5k | | 07/21/2022 |
| 06/24/2022 | A2A Pharmaceuticals, Inc. | 10% Owner | Sale | Common Stock | 34.7k | $11.76 | $407.6k | | 06/24/2022 |
| 06/22/2022 | Hitchcock Michael J.M. | Director | Grant | Stock Option (Right to Buy) | 23.9k | $10.20 | $243.4k | | 06/22/2022 |
| 06/22/2022 | Chen Bihua | 10% Owner | Grant | Stock Option (right to buy) | 23.9k | $10.20 | $243.4k | | 06/22/2022 |
| 06/22/2022 | AGUIAR ERIC | Director | Grant | Stock Option (Right to Buy) | 23.9k | $10.20 | $243.4k | | 06/22/2022 |
| 06/22/2022 | Faust Elizabeth | Director | Grant | Stock Option (Right to Buy) | 45.8k | $10.20 | $466.7k | | 06/22/2022 |
| 06/22/2022 | Ray Sumita | Director | Grant | Stock Option (Right to Buy) | 23.9k | $10.20 | $243.4k | | 06/22/2022 |
| 06/01/2022 | Biomea Health, LLC | 10% Owner | Other (disposition) | Common Stock | 4.4M | $0.00 | $0 | See Footnote | 06/01/2022 |
| 05/31/2022 | Valle Franco | CFO | Grant | Common Stock | 3.3k | $4.67 | $15.4k | | 05/31/2022 |
| 03/03/2022 | Ray Sumita | Director | Grant | Stock Option (Right to Buy) | 21.5k | $5.90 | $126.6k | | 03/03/2022 |
| 01/14/2022 | Valle Franco | CFO | Purchase | Common Stock | 10k | $8.68 | $86.8k | | 01/14/2022 |
| 12/04/2021 | Valle Franco | CFO | Grant | Stock Option (Right to Buy) | 144.8k | $9.80 | $1.4M | | 12/04/2021 |
| 12/04/2021 | Erdtmann Rainer M | President and COO | Grant | Stock Option (Right to Buy) | 165.5k | $9.80 | $1.6M | | 12/04/2021 |
| 12/04/2021 | Butler Thomas Andrew | CEO | Grant | Stock Option (Right to Buy) | 305.4k | $9.80 | $3M | | 12/04/2021 |
| 09/17/2021 | A2A Pharmaceuticals, Inc. | 10% Owner | Purchase | Common Stock | 34.7k | $10.96 | $379.9k | | 09/17/2021 |
| 09/17/2021 | Stergiopoulos Sotirios | Director | Purchase | Common Stock | 34.7k | $10.96 | $379.9k | See footnote | 09/17/2021 |
| 08/23/2021 | Butler Thomas Andrew | CEO | Purchase | Common Stock | 24k | $13.20 | $316.9k | See Footnote | 08/23/2021 |
|